A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients
JAMAPublished 25 March 1998
Julio Montaner, Peter Reiß, David A. Cooper, Stefano Vella, Marianne Harris, Brian Conway
Citations771
SJR quartileQ1
SJR score5.35
SNIP10.71
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied, suggesting that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.
Abstract
Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied. Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.
Keywords
Immunology and MicrobiologyMedicine
New England Journal of MedicineA Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
2,666 Citations1997Scott M. Hammer, Kathleen Squires +14 more
Treatment with indinavir, zidovudine, and lamivudine as compared with zidvudine and lam ivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidavudine.
Journal of Virological MethodsRapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
1,646 Citations1988Rudi Pauwels, Jan Balzarini +6 more
A rapid, sensitive and automated assay procedure was developed for the in vitro evaluation of anti-HIV agents, which significantly reduced labor time as compared to the trypan blue exclusion method, and permits the evaluation of large numbers of compounds for their anti-hIV activity.
New England Journal of MedicineA Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
1,088 Citations1996Scott M. Hammer, David Katzenstein +10 more
Antiretroviral therapy can improve survival in patients with 200 to 500 CD4 cells per cubic millimeter and is superior to treatment with zidovudine alone, although the benefits were limited to those without previous treatment.
JAMAAntiretroviral Therapy for HIV Infection in 1998
1,016 Citations1998Charles C. J. Carpenter, Margaret A. Fischl +12 more
Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection, and increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.
ScienceInhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor
746 Citations1990Vincent J. Merluzzi, Karl D. Hargrave +13 more
Dipyridodiazepinones inhibition of HIV-1 replication in vitro as demonstrated by in situ hybridization, inhibition of protein p24 production, and the lack of syncytia formation in cultured human T cell lines and freshly isolated human peripheral blood lymphocytes.
JAMAAntiretroviral Therapy for HIV Infection in 1997
728 Citations1997Charles C. J. Carpenter
New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence.
Journal of VirologyNevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
580 Citations1994Douglas D. Richman, Diane V. Havlir +8 more
Drug susceptibility and mutations in the reverse transcriptase (RT) gene were analyzed with virus isolates from 38 patients treated with nevirapine, a potent nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) RT, documenting that the circulating virus population can change rapidly, and many alternative mutants can emerge, often in complex mixtures.
Journal of Clinical MicrobiologyRapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection
568 Citations1994John E. Mulder, Nancy McKinney +4 more
A quantitative assay for viral RNA in plasma or sera that differs in several aspects from those reported previously was developed, and requires only a single amplification of the sample and can be completed in less than 8 h.
New England Journal of MedicineThe Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter
485 Citations1996David Katzenstein, Scott M. Hammer +10 more
Both the risk of the progression of HIV disease and the efficacy of antiretroviral therapy are strongly associated with the plasma level of HIV RNA and with the viral phenotype.
The Journal of Infectious DiseasesHigh-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus Infection
305 Citations1995Diane V. Havlir, Sarah H. Cheeseman +10 more
The data suggest that clinical testing of potent antiviral compounds that select for drug-resistant virus is justified to determine if serum levels of drug sufficient to overcome resistant virus can be attained.
The LancetRandomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial
247 Citations1997CAESAR Coordinating Committee, [Unknown], Study group members AMC, : +2 more
This dissertation aims to provide a history of web exceptionalism from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which descriptions of “Web 2.0” began to circulate.
Antimicrobial Agents and ChemotherapyRecombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
204 Citations1994Paul Kellam, Brendan Larder
The recombinant virus assay can be performed in approximately 3 weeks without the use of donor PBLs and therefore represents a rapid, nonselective procedure for the assay of clinical isolates.
The Journal of Infectious DiseasesInhibition of Human Immunodeficiency Virus Type I (HIV-I) Replication by the Dipyridodiazepinone BI-RG-587
110 Citations1991Richard A. Koup, V J Merluzzi +5 more
It is demonstrated that BI-RG-587 is a potent inhibitor of HIV-1 replication and that this inhibition occurs at the point of reverse transcription.
Antimicrobial Agents and ChemotherapyPharmacokinetics of nevirapine: initial single-rising-dose study in humans
102 Citations1993Sarah H. Cheeseman, Susan E. Hattox +8 more
The pharmacokinetic characteristics of nevirapine are appropriate for once-daily administration, and a daily 12.5-mg dose is predicted to achieve trough concentrations in plasma in the range required to totally inhibit replication of wild-type HIV-1 in human T-cell culture.
Journal of Biological ChemistryEffects of Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 in Cell-free Recombinant Reverse Transcriptase Assays
89 Citations1995Zhengxian Gu, Yudong Quan +3 more
A cell-free human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) assay is employed to study the effects of non-nucleoside inhibitors of RT (NNRTI) by directly monitoring specific HIV DNA products using a HIV-1 genome-derived template and an oligodeoxynucleotide primer.
AIDSA controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients
81 Citations1996Andrew Carr, Stefano Vella +5 more
Nevirapine exhibits significant although transient anti-HIV activity in ZDV-pretreated patients but its use is frequently associated with a hypersensitivity reaction.
Journal of Clinical MicrobiologyA rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity
79 Citations1997John E. Mulder, R Resnick +6 more
A rapid and simple technique for processing human immunodeficiency virus (HIV)-infected plasma by high-speed centrifugation, which has few manipulations and requires approximately 1.5 h for the processing of 24 samples.
The Journal of Infectious DiseasesPharmacokinetics, Safety, and Activity of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Children
78 Citations1996Katherine Luzuriaga, Yvonne J. Bryson +7 more
Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses, and clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more Rapid in younger children than in adolescent children.
Annals of Internal MedicineNevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection
74 Citations1996Richard T. D’Aquila, Michael D. Hughes +9 more
The Journal of Infectious DiseasesA Pilot Study to Evaluate the Development of Resistance to Nevirapine in Asymptomatic Human Immunodeficiency Virus-Infected Patients with CD4 Cell Counts of >500/mm3 : AIDS Clinical Trials Group Protocol 208
68 Citations1995Diane V. Havlir, Margaret McLaughlin +1 more
Results suggest that lower levels of HIV RNA and immunosuppression did not retard the rate of emergence of nevirapine-resistant virus; also, a polymerase chain reaction-based HIV RNA assay is sufficiently sensitive to evaluate the antiviral effect of a drug in patients with > 500 CD4 cells/mm3.
The Journal of Infectious DiseasesHigh‐Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1‐Infected Persons Does Not Result in Sustained Suppression of Viral Replication
68 Citations1997Menno D. de Jong, Stefano Vella +21 more
Observations suggest that plasma drug levels attained with high-dose nevirapine were not sufficient to inhibit ne virapine-resistant virus, although they were approximately 2-fold higher than reported IC50 values of resistant virus.
The Journal of Infectious DiseasesAlternating Nevirapine and Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Infected Persons Does Not Prolong Nevirapine Activity
33 Citations1994Menno D. de Jong, Mark Loewenthal +12 more
It is demonstrated that alternating treatment with zidovudine and nevirapine does not prolong the effectiveness of nevirAPine and does not prevent the development of ne virapine resistance.
AIDSThe effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count
25 Citations1998Julio Montaner, Ralph DeMasi +1 more
Rises in CD4 cell count and reductions in HIV-1 RNA were reliable in predicting the clinical benefit of 3TC in the CAESAR trial and predicted a 59% reduction in progression to AIDS or death.